Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) had its target price cut by equities researchers at Laidlaw from $118.00 to $90.00 in a research note issued to investors on Friday. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Laidlaw’s price target would indicate a potential upside of 46.13% from the company’s current price.

ICPT has been the subject of a number of other research reports. Cowen and Company reissued an “outperform” rating and set a $232.00 price target on shares of Intercept Pharmaceuticals in a research report on Thursday, September 14th. BMO Capital Markets raised their price target on shares of Intercept Pharmaceuticals from $218.00 to $221.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 1st. BidaskClub raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 24th. Cantor Fitzgerald reissued an “underweight” rating and set a $69.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Citigroup Inc. reissued a “neutral” rating and set a $150.00 price target on shares of Intercept Pharmaceuticals in a research report on Tuesday, September 19th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Intercept Pharmaceuticals presently has an average rating of “Hold” and an average price target of $174.93.

Intercept Pharmaceuticals (NASDAQ ICPT) opened at 61.59 on Friday. The stock’s market cap is $1.55 billion. Intercept Pharmaceuticals has a 52 week low of $60.97 and a 52 week high of $172.95. The company has a 50-day moving average of $106.75 and a 200-day moving average of $115.74.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The company had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. During the same quarter last year, the company earned ($3.14) earnings per share. Intercept Pharmaceuticals’s revenue for the quarter was up 459.6% on a year-over-year basis. On average, analysts predict that Intercept Pharmaceuticals will post ($13.91) EPS for the current fiscal year.

WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Price Target Cut to $90.00” was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/09/24/intercept-pharmaceuticals-inc-icpt-price-target-cut-to-90-00.html.

In other Intercept Pharmaceuticals news, insider Lisa Bright sold 253 shares of the firm’s stock in a transaction on Friday, August 25th. The stock was sold at an average price of $111.31, for a total value of $28,161.43. Following the sale, the insider now directly owns 23,324 shares in the company, valued at $2,596,194.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CMO David Shapiro sold 1,250 shares of the firm’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $117.43, for a total value of $146,787.50. Following the completion of the sale, the chief marketing officer now owns 45,812 shares in the company, valued at $5,379,703.16. The disclosure for this sale can be found here. Insiders sold 48,013 shares of company stock worth $6,198,747 over the last quarter. 9.20% of the stock is currently owned by company insiders.

Hedge funds have recently bought and sold shares of the business. WFG Advisors LP lifted its stake in Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 125 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares during the last quarter. US Bancorp DE bought a new stake in Intercept Pharmaceuticals in the first quarter valued at $130,000. IFP Advisors Inc lifted its stake in Intercept Pharmaceuticals by 128.1% in the second quarter. IFP Advisors Inc now owns 1,300 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 730 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Intercept Pharmaceuticals in the first quarter valued at $170,000. Institutional investors own 82.19% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.